Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...
Aramark (ARMK) is expected to report $0.49 for 4Q. Astria Therapeutics Inc (ATXS) is expected to report $-0.44 for 3Q. Bellerophon Therapeutics Inc (BLPH) is expected to report for 3Q. Black Diamond ...
GrowthCap is pleased to announce The Top Private Debt Firms of 2024. In an era when companies, primarily in the middle market, are focused on identifying capital providers who are flexible and can act ...
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Black Diamond Therapeutics, Inc. (BDTX) on Tuesday reported a loss of $15.6 million in its third quarter. The Cambridge, Massachusetts-based company ...
Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 ...